Difference between revisions of "Florid epithelial hyperplasia"

From Libre Pathology
Jump to navigation Jump to search
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{ Infobox diagnosis
| Name      = {{PAGENAME}}
| Image      = Proliferative fibrocystic changes -- intermed mag.jpg
| Width      =
| Caption    = Proliferative fibrocystic changes (''florid epithelial hyperplasia'' together with ''fibrocystic breast changes''). [[H&E stain]].
| Synonyms  = florid epithelial hyperplasia of the usual type, usual ductal hyperplasia, moderate epithelial hyperplasia
| Micro      = breast glands with more than four cell layers above the basement membrane with irregular cell spacing (e.g. streaming), slit-like lumina (esp. at the periphery of the duct), no [[DCIS]]-like architecture (not [[cribriform]], not papillary, not micropapillary, not solid), no nuclear atypia - usually no [[nucleoli]]
| Subtypes  =
| LMDDx      = [[mild epithelial hyperplasia]], [[atypical ductal hyperplasia]], cribriform [[ductal carcinoma in situ]]
| Stains    =
| IHC        = ER "low" (see below), CK5 "high" (see below)
| EM        =
| Molecular  =
| IF        =
| Gross      =
| Grossing  =
| Site      = [[breast]]
| Assdx      = [[fibrocystic breast changes]] (FEH + FCC = ''proliferative fibrocystic changes'')
| Syndromes  =
| Clinicalhx = usually an incidental finding
| Signs      =
| Symptoms  =
| Prevalence = common
| Bloodwork  =
| Rads      =
| Endoscopy  =
| Prognosis  = benign, increased risk of [[breast cancer]]
| Other      =
| ClinDDx    =
| Tx        =
}}
'''Florid epithelial hyperplasia''', abbreviated '''FEH''', is a common benign [[breast pathology]] finding that is associated with a mild increased risk of [[breast cancer]].
'''Florid epithelial hyperplasia''', abbreviated '''FEH''', is a common benign [[breast pathology]] finding that is associated with a mild increased risk of [[breast cancer]].


Line 5: Line 36:
Confusingly, it may be referred to as ''epithelial hyperplasia'', term that is best avoided, as it could lead to confusion with ''[[mild epithelial hyperplasia]]''.
Confusingly, it may be referred to as ''epithelial hyperplasia'', term that is best avoided, as it could lead to confusion with ''[[mild epithelial hyperplasia]]''.


'''Moderate epithelial hyperplasia''' redirects to this article, as it is usually lumped with FEH.
'''Moderate epithelial hyperplasia''' redirects to this article, as it is usually lumped with FEH. '''Proliferative fibrocystic changes''' (abbreviated '''PFCC''') redirects to this article.


==General==
==General==
Line 20: Line 51:
*Irregular cell spacing; streaming.
*Irregular cell spacing; streaming.
*Slit-like lumina, esp. at the periphery of the duct.
*Slit-like lumina, esp. at the periphery of the duct.
*No [[DCIS]]-like architecture (not cribriform, not papillary, not micropapillary, not solid).
*No [[DCIS]]-like architecture (not [[cribriform]], not papillary, not micropapillary, not solid).
*No nuclear atypia - usually no [[nucleoli]].
*No nuclear atypia - usually no [[nucleoli]].


Line 30: Line 61:
*[[Atypical ductal hyperplasia]].
*[[Atypical ductal hyperplasia]].
*Cribriform [[ductal carcinoma in situ]]
*Cribriform [[ductal carcinoma in situ]]
===Images===
<gallery>
Image: Proliferative fibrocystic changes -- low mag.jpg |PFCC - low mag.
Image: Proliferative fibrocystic changes -- intermed mag.jpg |PFCC - intermed. mag.
Image: Proliferative fibrocystic changes -- high mag.jpg |PFCC - high mag.
Image: Proliferative fibrocystic changes -- very high mag.jpg|PFCC - very high mag.
</gallery>
==IHC==
Features:<ref name=pmid19675450>{{Cite journal  | last1 = Grin | first1 = A. | last2 = O'Malley | first2 = FP. | last3 = Mulligan | first3 = AM. | title = Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. | journal = Am J Surg Pathol | volume = 33 | issue = 11 | pages = 1615-23 | month = Nov | year = 2009 | doi = 10.1097/PAS.0b013e3181aec446 | PMID = 19675450 }}</ref>
*ER "low".
*CK5 "high".
Where:
*ER "high" = diffuse strong staining in >90% of cells.
*CK5 "high" = mosaic pattern of staining in >20% of cells
*CK5 "low" = absent or staining in <20% of cells.
Note:
*ADH/DCIS:
**ER "high"
**CK5 "low".


==Sign out==
==Sign out==
<pre>
A. Left Breast (795 grams), Reduction Mammoplasty:
- Benign breast tissue with usual ductal hyperplasia and skin within normal limits.
B. Right Breast (685 grams), Reduction Mammoplasty:
- Benign breast tissue and skin within normal limits.
</pre>
===UDH with cystic changes===
<pre>
<pre>
A. Right Breast (570 grams), Reduction Mammoplasty:
A. Right Breast (570 grams), Reduction Mammoplasty:
Line 46: Line 109:
==See also==
==See also==
*[[Breast pathology]].
*[[Breast pathology]].
*[[Atypical ductal hyperplasia]].


==References==
==References==

Latest revision as of 13:53, 2 September 2021

Florid epithelial hyperplasia
Diagnosis in short

Proliferative fibrocystic changes (florid epithelial hyperplasia together with fibrocystic breast changes). H&E stain.

Synonyms florid epithelial hyperplasia of the usual type, usual ductal hyperplasia, moderate epithelial hyperplasia

LM breast glands with more than four cell layers above the basement membrane with irregular cell spacing (e.g. streaming), slit-like lumina (esp. at the periphery of the duct), no DCIS-like architecture (not cribriform, not papillary, not micropapillary, not solid), no nuclear atypia - usually no nucleoli
LM DDx mild epithelial hyperplasia, atypical ductal hyperplasia, cribriform ductal carcinoma in situ
IHC ER "low" (see below), CK5 "high" (see below)
Site breast

Associated Dx fibrocystic breast changes (FEH + FCC = proliferative fibrocystic changes)
Clinical history usually an incidental finding
Prevalence common
Prognosis benign, increased risk of breast cancer

Florid epithelial hyperplasia, abbreviated FEH, is a common benign breast pathology finding that is associated with a mild increased risk of breast cancer.

It is also known as florid epithelial hyperplasia of the usual type (abbreviated FEHUT) and usual ductal hyperplasia (abbreviated UDH).

Confusingly, it may be referred to as epithelial hyperplasia, term that is best avoided, as it could lead to confusion with mild epithelial hyperplasia.

Moderate epithelial hyperplasia redirects to this article, as it is usually lumped with FEH. Proliferative fibrocystic changes (abbreviated PFCC) redirects to this article.

General

Note:

  • Moderate epithelial hyperplasia redirects to this section.
    • It is generally not separated from FEH, as the prognosis is thought to be the same.

Microscopic

Features:[2]

  • Breast glands with more than four cell layers above the basement membrane - key feature.
  • Irregular cell spacing; streaming.
  • Slit-like lumina, esp. at the periphery of the duct.
  • No DCIS-like architecture (not cribriform, not papillary, not micropapillary, not solid).
  • No nuclear atypia - usually no nucleoli.

Memory device CLEAN:

  • Cell spacing is irregular, Lumina are slit-like, Extent is less than 2 mm or 2 ducts, Architecture not DCIS-like, Nuclear atypia not present.

DDx:

Images

IHC

Features:[3]

  • ER "low".
  • CK5 "high".

Where:

  • ER "high" = diffuse strong staining in >90% of cells.
  • CK5 "high" = mosaic pattern of staining in >20% of cells
  • CK5 "low" = absent or staining in <20% of cells.

Note:

  • ADH/DCIS:
    • ER "high"
    • CK5 "low".

Sign out

A. Left Breast (795 grams), Reduction Mammoplasty:
- Benign breast tissue with usual ductal hyperplasia and skin within normal limits.

B. Right Breast (685 grams), Reduction Mammoplasty:
- Benign breast tissue and skin within normal limits.

UDH with cystic changes

A. Right Breast (570 grams), Reduction Mammoplasty:
- Benign breast tissue with proliferative fibrocystic changes.
- Benign skin.

B. Left Breast (580 grams), Reduction Mammoplasty:
- Breast tissue and skin within normal limits.

Note:

See also

References

  1. Mitchell, Richard; Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Aster, Jon (2011). Pocket Companion to Robbins & Cotran Pathologic Basis of Disease (8th ed.). Elsevier Saunders. pp. 542. ISBN 978-1416054542.
  2. O'Malley, Frances P.; Pinder, Sarah E. (2006). Breast Pathology: A Volume in Foundations in Diagnostic Pathology series (1st ed.). Churchill Livingstone. pp. 159-160. ISBN 978-0443066801.
  3. Grin, A.; O'Malley, FP.; Mulligan, AM. (Nov 2009). "Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.". Am J Surg Pathol 33 (11): 1615-23. doi:10.1097/PAS.0b013e3181aec446. PMID 19675450.